Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Mostrar otras versiones (1)

The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenke, Kyle, Hansen, Frederick, Schwarz, Benjamin, Feldmann, Friederike, Haddock, Elaine, Rosenke, Rebecca, Barbian, Kent, Meade-White, Kimberly, Okumura, Atsushi, Leventhal, Shanna, Hawman, David W., Ricotta, Emily, Bosio, Catharine M., Martens, Craig, Saturday, Greg, Feldmann, Heinz, Jarvis, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052374/
https://www.ncbi.nlm.nih.gov/pubmed/33863887
http://dx.doi.org/10.1038/s41467-021-22580-8
_version_ 1783679907613638656
author Rosenke, Kyle
Hansen, Frederick
Schwarz, Benjamin
Feldmann, Friederike
Haddock, Elaine
Rosenke, Rebecca
Barbian, Kent
Meade-White, Kimberly
Okumura, Atsushi
Leventhal, Shanna
Hawman, David W.
Ricotta, Emily
Bosio, Catharine M.
Martens, Craig
Saturday, Greg
Feldmann, Heinz
Jarvis, Michael A.
author_facet Rosenke, Kyle
Hansen, Frederick
Schwarz, Benjamin
Feldmann, Friederike
Haddock, Elaine
Rosenke, Rebecca
Barbian, Kent
Meade-White, Kimberly
Okumura, Atsushi
Leventhal, Shanna
Hawman, David W.
Ricotta, Emily
Bosio, Catharine M.
Martens, Craig
Saturday, Greg
Feldmann, Heinz
Jarvis, Michael A.
author_sort Rosenke, Kyle
collection PubMed
description The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.
format Online
Article
Text
id pubmed-8052374
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80523742021-05-11 Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model Rosenke, Kyle Hansen, Frederick Schwarz, Benjamin Feldmann, Friederike Haddock, Elaine Rosenke, Rebecca Barbian, Kent Meade-White, Kimberly Okumura, Atsushi Leventhal, Shanna Hawman, David W. Ricotta, Emily Bosio, Catharine M. Martens, Craig Saturday, Greg Feldmann, Heinz Jarvis, Michael A. Nat Commun Article The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients. Nature Publishing Group UK 2021-04-16 /pmc/articles/PMC8052374/ /pubmed/33863887 http://dx.doi.org/10.1038/s41467-021-22580-8 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Rosenke, Kyle
Hansen, Frederick
Schwarz, Benjamin
Feldmann, Friederike
Haddock, Elaine
Rosenke, Rebecca
Barbian, Kent
Meade-White, Kimberly
Okumura, Atsushi
Leventhal, Shanna
Hawman, David W.
Ricotta, Emily
Bosio, Catharine M.
Martens, Craig
Saturday, Greg
Feldmann, Heinz
Jarvis, Michael A.
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title_full Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title_fullStr Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title_full_unstemmed Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title_short Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title_sort orally delivered mk-4482 inhibits sars-cov-2 replication in the syrian hamster model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052374/
https://www.ncbi.nlm.nih.gov/pubmed/33863887
http://dx.doi.org/10.1038/s41467-021-22580-8
work_keys_str_mv AT rosenkekyle orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT hansenfrederick orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT schwarzbenjamin orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT feldmannfriederike orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT haddockelaine orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT rosenkerebecca orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT barbiankent orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT meadewhitekimberly orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT okumuraatsushi orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT leventhalshanna orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT hawmandavidw orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT ricottaemily orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT bosiocatharinem orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT martenscraig orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT saturdaygreg orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT feldmannheinz orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
AT jarvismichaela orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel

Ejemplares similares